Bioage Labs Inc. is advancing its apelin receptor (APJ) agonist programs for obesity and other indications, and has entered into an option agreement with Jikang Therapeutics to license a novel APJ ...
Interest in metabolic medicines is riding high, led by the popular class of weight management drugs known as GLP-1 agonists. BioAge Labs aims to help those medications work better with a lead drug ...
Bioage Labs Inc.’s $170 million series D financing will pay for phase II trials with azelaprag, an apelin receptor agonist, to be tried in combination with Zepbound (tirzepatide), the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results